Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SCYNEXIS Inc SCYX

Healthcare
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.


NDAQ:SCYX - Post by User

SCYNEXIS Inc > BREXAFEMME - published User side effects
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by GMA133on Feb 07, 2022 3:22pm
139 Views
Post# 34406017

BREXAFEMME - published User side effects

BREXAFEMME - published User side effects

Join me by taking your action by contacting SCYX Investor Relations.

 

Today, I emailed Irina of SCYX - Investor Relations & recommended that Marco Taglietti, M.D.  launch a positive, enthusiastic & aggressive PR campaign ASAP, using many BREXAFEMME user experiences with their side effects, etc. SCYX should also comment on serious side effects, especially if these type of reactions are the (unfortunate) result of very serious rVVR infections.

I attached the WebMD web link below regarding the revues by the cohort of 7 that used BREXAFEMME.

 

Irina thanked me & advised that she would forward my recommendations to SCYX executive management.

 

 GLTAL

 

 

https://www.webmd.com/drugs/drugreview-181690-brexafemme-oral

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities